Carlo Piccinni1, Ippazio Cosimo Antonazzo2,3, Aldo P Maggioni4,5, Antonella Pedrini4, Silvia Calabria4, Giulia Ronconi4, Letizia Dondi4, Nello Martini4, Giuseppe Roberto2, Tiziana Sampietro6, Francesco Sbrana6, Beatrice Dal Pino6, Federico Bigazzi6, Giuseppa Lo Surdo7, Elisabetta Volpi7, Stefania Biagini7, Rosa Gini2. 1. Fondazione ReS (Ricerca e Salute)-Research and Health Foundation, Via Magnanelli 2, Casalecchio di Reno, 40033, Bologna, Italy. piccinni@fondazioneres.it. 2. Epidemiology Unit, Regional Agency for Healthcare Services of Tuscany, Florence, Italy. 3. Pharmacology Unit, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. 4. Fondazione ReS (Ricerca e Salute)-Research and Health Foundation, Via Magnanelli 2, Casalecchio di Reno, 40033, Bologna, Italy. 5. ANMCO Research Centre, Florence, Italy. 6. Lipoapheresis Unit, Reference Centre for Diagnosis and Treatment of Inherited Dyslipidaemias, Fondazione Toscana Gabriele Monasterio, Pisa, Italy. 7. Hospital Pharmacy, Fondazione Toscana Gabriele Monasterio, Massa, Italy.
Abstract
BACKGROUND AND OBJECTIVE: Cardiovascular (CV) diseases represent a major cause of death and severe medical condition worldwide. Different therapeutic options are available to control low-density lipoprotein cholesterol (LDL-C) level in order to prevent CV events. In recent years, two new drugs were approved for patients who are unable to reduce circulating LDL-C with the current therapies: evolocumab and alirocumab (proprotein convertase subtilisin/kexin type nine [PCSK9] inhibitors). This study was aimed to characterise patients who started treatment with PCSK9 inhibitors in the Tuscany region of Italy during the first year of public healthcare service reimbursement and to describe the pattern of PCSK9 inhibitor use in the first 6 months of treatment. METHODS: Patients on PCSK9 inhibitor treatment in Tuscany (3.7 million inhabitants) from 07/2017 to 06/2018 were selected from regional healthcare administrative databases. Concomitant use of lipid-lowering therapies (LLTs), adherence and persistence during the 6 months preceding the first PCSK9 inhibitor dispensing, as well as comorbidities since 1996, were described. In the first 6 months of PCSK9 inhibitor treatment, adherence, persistence and concomitant LLTs were assessed. RESULTS: There were 269 (176 evolocumab, 93 alirocumab) new users of PCSK9 inhibitors. Patients (mean age of 59.1 years) were mainly male (71.0%) in secondary prevention (70.2%) and affected by familial hypercholesterolaemia (53.5%). Sixty-six patients (24.5%) had diabetes mellitus and 12 (4.5%) chronic renal failure. In the 6 months prior to the first PCSK9 inhibitor administration, 61.3% of patients received at least one prescription of ezetimibe or high-intensity statins and 45.7% were persistent to these drugs. During follow-up, 79.9% of patients were adherent to PCSK9 inhibitor and 73.3% were persistent. CONCLUSIONS: During the first year of availability, the rate of prescription of PCSK9 inhibitors appears below expectations. Patients were mainly in secondary prevention and had been slightly persistent to previous LLTs. During follow-up, the PCSK9 inhibitor monotherapy showed high levels of adherence and persistence. This real-world study sets the stage for future longer-term investigations useful to improve our knowledge on the appropriateness, drug access and public healthcare sustainability of PCSK9 inhibitors.
BACKGROUND AND OBJECTIVE:Cardiovascular (CV) diseases represent a major cause of death and severe medical condition worldwide. Different therapeutic options are available to control low-density lipoprotein cholesterol (LDL-C) level in order to prevent CV events. In recent years, two new drugs were approved for patients who are unable to reduce circulating LDL-C with the current therapies: evolocumab and alirocumab (proprotein convertase subtilisin/kexin type nine [PCSK9] inhibitors). This study was aimed to characterise patients who started treatment with PCSK9 inhibitors in the Tuscany region of Italy during the first year of public healthcare service reimbursement and to describe the pattern of PCSK9 inhibitor use in the first 6 months of treatment. METHODS:Patients on PCSK9 inhibitor treatment in Tuscany (3.7 million inhabitants) from 07/2017 to 06/2018 were selected from regional healthcare administrative databases. Concomitant use of lipid-lowering therapies (LLTs), adherence and persistence during the 6 months preceding the first PCSK9 inhibitor dispensing, as well as comorbidities since 1996, were described. In the first 6 months of PCSK9 inhibitor treatment, adherence, persistence and concomitant LLTs were assessed. RESULTS: There were 269 (176 evolocumab, 93 alirocumab) new users of PCSK9 inhibitors. Patients (mean age of 59.1 years) were mainly male (71.0%) in secondary prevention (70.2%) and affected by familial hypercholesterolaemia (53.5%). Sixty-six patients (24.5%) had diabetes mellitus and 12 (4.5%) chronic renal failure. In the 6 months prior to the first PCSK9 inhibitor administration, 61.3% of patients received at least one prescription of ezetimibe or high-intensity statins and 45.7% were persistent to these drugs. During follow-up, 79.9% of patients were adherent to PCSK9 inhibitor and 73.3% were persistent. CONCLUSIONS: During the first year of availability, the rate of prescription of PCSK9 inhibitors appears below expectations. Patients were mainly in secondary prevention and had been slightly persistent to previous LLTs. During follow-up, the PCSK9 inhibitor monotherapy showed high levels of adherence and persistence. This real-world study sets the stage for future longer-term investigations useful to improve our knowledge on the appropriateness, drug access and public healthcare sustainability of PCSK9 inhibitors.
Authors: Giovanni Corrao; Matteo Monzio Compagnoni; Matteo Franchi; Anna Cantarutti; Pietro Pugni; Luca Merlino; Alberico L Catapano; Giuseppe Mancia Journal: Eur J Intern Med Date: 2017-09-27 Impact factor: 4.487
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: Circulation Date: 2018-11-10 Impact factor: 29.690
Authors: Robert M Stoekenbroek; Merel L Hartgers; Roger Rutte; Douwe D de Wijer; Erik S G Stroes; G Kees Hovingh Journal: Atherosclerosis Date: 2017-12-01 Impact factor: 5.162
Authors: Omar Razek; Lubormira Cermakova; Hamidreza Armani; Terry Lee; Gordon A Francis; G B John Mancini; Jiri Frohlich; Liam R Brunham Journal: Can J Cardiol Date: 2018-04-20 Impact factor: 5.223
Authors: Amand F Schmidt; Lucy S Pearce; John T Wilkins; John P Overington; Aroon D Hingorani; Juan P Casas Journal: Cochrane Database Syst Rev Date: 2017-04-28
Authors: Aris Karatasakis; Barbara A Danek; Judit Karacsonyi; Bavana V Rangan; Michele K Roesle; Thomas Knickelbine; Michael D Miedema; Houman Khalili; Zahid Ahmad; Shuaib Abdullah; Subhash Banerjee; Emmanouil S Brilakis Journal: J Am Heart Assoc Date: 2017-12-09 Impact factor: 5.501
Authors: Gabriella di Mauro; Alessia Zinzi; Cristina Scavone; Francesco Rossi; Annalisa Capuano; Annamaria Mascolo; Mario Gaio; Liberata Sportiello; Carmen Ferrajolo; Concetta Rafaniello Journal: Drug Saf Date: 2020-12-22 Impact factor: 5.606
Authors: Tim Hollstein; Ursula Kassner; Thomas Grenkowitz; Friederike Schumann; Thomas Bobbert; Elisabeth Steinhagen-Thiessen Journal: Am J Cardiovasc Drugs Date: 2021-01 Impact factor: 3.571
Authors: Daniel I Swerdlow; David A Rider; Arash Yavari; Marie Wikström Lindholm; Giles V Campion; Steven E Nissen Journal: Cardiovasc Res Date: 2022-03-25 Impact factor: 10.787